Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia
- PMID: 40293670
- DOI: 10.1007/s11912-025-01678-y
Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia
Abstract
Purpose of review: Despite differences in the various classification systems of acute myeloid leukemia (AML), rare entities can be identified according to clinical, biological or morphological characteristics. Uncommon AML defined on specific morphological criteria and/or genetic abnormalities were considered if occurring with a frequency of ≤ 5% in adult patients with AML.
Recent findings: Most of uncommon AML are characterized by a poor outcome with the standard treatment approaches. During the last decade, several therapeutic drugs with promising investigational approaches have been used in therapeutic regimens in both frontline and relapsed/refractory AML and represent a positive potential benefit for some rare entities displaying specific molecular lesions. Several rare subtypes can be identified in adult patients with AML. In this descriptive review, we assess the available information for these rare entities and summarized treatments that could be proposed especially according to their genetic characterization.
Keywords: Diagnosis; Genetic profile; Morphological criteria; Outcome; Rare leukemias; Treatment.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by the author. Competing Interests: The author declares no competing interests.
Similar articles
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
-
A systematic overview of chemotherapy effects in acute myeloid leukaemia.Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321. Acta Oncol. 2001. PMID: 11441935
-
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28. Future Oncol. 2025. PMID: 39606837
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Thomas XG. Rare acute leukemias. SM Ansell, editor Rare hematological malignancies. Springer. 2008; 149–191.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials